CN116064755B - 一种基于连锁基因突变检测mrd标志物的装置 - Google Patents
一种基于连锁基因突变检测mrd标志物的装置 Download PDFInfo
- Publication number
- CN116064755B CN116064755B CN202310063877.4A CN202310063877A CN116064755B CN 116064755 B CN116064755 B CN 116064755B CN 202310063877 A CN202310063877 A CN 202310063877A CN 116064755 B CN116064755 B CN 116064755B
- Authority
- CN
- China
- Prior art keywords
- mutation
- snv
- linkage
- mutations
- sequencing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010064571 Gene mutation Diseases 0.000 title claims abstract description 11
- 239000003550 marker Substances 0.000 title abstract description 6
- 230000035772 mutation Effects 0.000 claims abstract description 494
- 238000012163 sequencing technique Methods 0.000 claims abstract description 110
- 238000012544 monitoring process Methods 0.000 claims abstract description 80
- 238000000034 method Methods 0.000 claims abstract description 69
- 239000012634 fragment Substances 0.000 claims abstract description 66
- 238000001514 detection method Methods 0.000 claims abstract description 57
- 238000010276 construction Methods 0.000 claims abstract description 21
- 210000004369 blood Anatomy 0.000 claims abstract description 12
- 239000008280 blood Substances 0.000 claims abstract description 12
- 239000000523 sample Substances 0.000 claims description 141
- 206010028980 Neoplasm Diseases 0.000 claims description 66
- 238000004364 calculation method Methods 0.000 claims description 47
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 46
- 239000011159 matrix material Substances 0.000 claims description 44
- 230000036438 mutation frequency Effects 0.000 claims description 44
- 238000003745 diagnosis Methods 0.000 claims description 36
- 238000001914 filtration Methods 0.000 claims description 29
- 210000000349 chromosome Anatomy 0.000 claims description 24
- 238000012216 screening Methods 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 17
- 210000004602 germ cell Anatomy 0.000 claims description 14
- 230000001717 pathogenic effect Effects 0.000 claims description 12
- 238000012360 testing method Methods 0.000 claims description 12
- 238000002372 labelling Methods 0.000 claims description 11
- 230000002159 abnormal effect Effects 0.000 claims description 10
- 238000012545 processing Methods 0.000 claims description 10
- 230000008859 change Effects 0.000 claims description 9
- 238000010998 test method Methods 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 238000005070 sampling Methods 0.000 claims description 7
- 238000003780 insertion Methods 0.000 claims description 6
- 230000037431 insertion Effects 0.000 claims description 6
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 claims description 4
- 230000002759 chromosomal effect Effects 0.000 claims description 4
- 230000003902 lesion Effects 0.000 claims description 4
- 210000001161 mammalian embryo Anatomy 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000005516 engineering process Methods 0.000 abstract description 16
- 108090000623 proteins and genes Proteins 0.000 abstract description 10
- 238000007796 conventional method Methods 0.000 abstract description 6
- 238000002474 experimental method Methods 0.000 abstract description 6
- 238000000684 flow cytometry Methods 0.000 abstract description 6
- 238000012806 monitoring device Methods 0.000 abstract description 4
- 208000027418 Wounds and injury Diseases 0.000 abstract description 3
- 230000006378 damage Effects 0.000 abstract description 3
- 238000011156 evaluation Methods 0.000 abstract description 3
- 208000014674 injury Diseases 0.000 abstract description 3
- 230000002980 postoperative effect Effects 0.000 abstract description 3
- 238000004445 quantitative analysis Methods 0.000 abstract description 3
- 230000002285 radioactive effect Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 14
- 238000004422 calculation algorithm Methods 0.000 description 13
- 210000002381 plasma Anatomy 0.000 description 10
- 210000005259 peripheral blood Anatomy 0.000 description 9
- 239000011886 peripheral blood Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 8
- 238000012070 whole genome sequencing analysis Methods 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 238000004891 communication Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000007481 next generation sequencing Methods 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000003908 quality control method Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000004088 simulation Methods 0.000 description 3
- 108091092584 GDNA Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 238000007847 digital PCR Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000000053 physical method Methods 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 206010065163 Clonal evolution Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 238000012614 Monte-Carlo sampling Methods 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/50—Mutagenesis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
- G16B50/30—Data warehousing; Computing architectures
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02D—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN INFORMATION AND COMMUNICATION TECHNOLOGIES [ICT], I.E. INFORMATION AND COMMUNICATION TECHNOLOGIES AIMING AT THE REDUCTION OF THEIR OWN ENERGY USE
- Y02D10/00—Energy efficient computing, e.g. low power processors, power management or thermal management
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Theoretical Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Pathology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biochemistry (AREA)
- Databases & Information Systems (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Bioethics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310063877.4A CN116064755B (zh) | 2023-01-12 | 2023-01-12 | 一种基于连锁基因突变检测mrd标志物的装置 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310063877.4A CN116064755B (zh) | 2023-01-12 | 2023-01-12 | 一种基于连锁基因突变检测mrd标志物的装置 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116064755A CN116064755A (zh) | 2023-05-05 |
CN116064755B true CN116064755B (zh) | 2023-10-20 |
Family
ID=86169500
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310063877.4A Active CN116064755B (zh) | 2023-01-12 | 2023-01-12 | 一种基于连锁基因突变检测mrd标志物的装置 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116064755B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116959579B (zh) * | 2023-09-19 | 2023-12-22 | 北京求臻医学检验实验室有限公司 | 一种用于降低二代测序系统错误的系统 |
CN117373527A (zh) * | 2023-12-07 | 2024-01-09 | 中国科学院微生物研究所 | Hiv序列质控方法、设备及存储介质 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103221551A (zh) * | 2010-11-23 | 2013-07-24 | 深圳华大基因科技有限公司 | Hla基因型别-snp连锁数据库、其构建方法、以及hla分型方法 |
WO2016078067A1 (zh) * | 2014-11-21 | 2016-05-26 | 深圳华大基因研究院 | 个体单核苷酸多态性位点分型方法及装置 |
CN107002093A (zh) * | 2014-06-26 | 2017-08-01 | 瑞泽恩制药公司 | 用于靶向遗传修饰的方法和组合物,以及这些组合物的使用方法 |
CN113174431A (zh) * | 2021-03-11 | 2021-07-27 | 厦门市妇幼保健院(厦门市计划生育服务中心) | Topovibl作为靶标在诊断和治疗非梗阻性无精子症中的应用 |
CN113284554A (zh) * | 2021-04-28 | 2021-08-20 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | 一种筛查结直肠癌术后微小残留病灶及预测复发风险的循环肿瘤dna检测系统及应用 |
CN114187964A (zh) * | 2021-12-13 | 2022-03-15 | 深圳市海普洛斯生物科技有限公司 | 一种肺癌围手术期分子残留病灶基因检测panel及检测模型的构建方法 |
CN114292912A (zh) * | 2021-12-24 | 2022-04-08 | 广州燃石医学检验所有限公司 | 一种变体核酸的检测方法 |
CN115491423A (zh) * | 2022-09-23 | 2022-12-20 | 珠海横琴铂华医学检验有限公司 | 一种用于b细胞淋巴瘤mrd监测的基因组合、试剂盒与应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019055835A1 (en) * | 2017-09-15 | 2019-03-21 | The Regents Of The University Of California | DETECTION OF SOMATIC MONONUCLEOTIDE VARIANTS FROM ACELLULAR NUCLEIC ACID WITH APPLICATION TO MINIMUM RESIDUAL DISEASE SURVEILLANCE |
US11781189B2 (en) * | 2019-08-27 | 2023-10-10 | Fundación Para La Investigación Biomédica Del Hospital Universitario 12 De Octubre | Method for determining the presence or absence of minimal residual disease (MRD) in a subject who has been treated for a disease |
-
2023
- 2023-01-12 CN CN202310063877.4A patent/CN116064755B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103221551A (zh) * | 2010-11-23 | 2013-07-24 | 深圳华大基因科技有限公司 | Hla基因型别-snp连锁数据库、其构建方法、以及hla分型方法 |
CN107002093A (zh) * | 2014-06-26 | 2017-08-01 | 瑞泽恩制药公司 | 用于靶向遗传修饰的方法和组合物,以及这些组合物的使用方法 |
WO2016078067A1 (zh) * | 2014-11-21 | 2016-05-26 | 深圳华大基因研究院 | 个体单核苷酸多态性位点分型方法及装置 |
CN113174431A (zh) * | 2021-03-11 | 2021-07-27 | 厦门市妇幼保健院(厦门市计划生育服务中心) | Topovibl作为靶标在诊断和治疗非梗阻性无精子症中的应用 |
CN113284554A (zh) * | 2021-04-28 | 2021-08-20 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | 一种筛查结直肠癌术后微小残留病灶及预测复发风险的循环肿瘤dna检测系统及应用 |
CN114187964A (zh) * | 2021-12-13 | 2022-03-15 | 深圳市海普洛斯生物科技有限公司 | 一种肺癌围手术期分子残留病灶基因检测panel及检测模型的构建方法 |
CN114292912A (zh) * | 2021-12-24 | 2022-04-08 | 广州燃石医学检验所有限公司 | 一种变体核酸的检测方法 |
CN115491423A (zh) * | 2022-09-23 | 2022-12-20 | 珠海横琴铂华医学检验有限公司 | 一种用于b细胞淋巴瘤mrd监测的基因组合、试剂盒与应用 |
Non-Patent Citations (3)
Title |
---|
Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives;Yan Peng等;Front Oncol.;第1-14页 * |
白血病基因诊断及其信息系统建立;孙新六;中国实验诊断学;第1182-1184页 * |
过继细胞转输治疗白血病微小残留病灶治疗效果的Meta分析;张庆义;世界最新医学信息文摘;第88-89页 * |
Also Published As
Publication number | Publication date |
---|---|
CN116064755A (zh) | 2023-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7051900B2 (ja) | 不均一分子長を有するユニーク分子インデックスセットの生成およびエラー補正のための方法およびシステム | |
CN116064755B (zh) | 一种基于连锁基因突变检测mrd标志物的装置 | |
CN110800063B (zh) | 使用无细胞dna片段大小检测肿瘤相关变体 | |
CN104781421B (zh) | 检测稀有突变和拷贝数变异的系统和方法 | |
EP2926288B1 (en) | Accurate and fast mapping of targeted sequencing reads | |
CN112086129B (zh) | 预测肿瘤组织cfDNA的方法及系统 | |
CN106156543B (zh) | 一种肿瘤ctDNA信息统计方法 | |
CN114574581A (zh) | 检测稀有突变和拷贝数变异的系统和方法 | |
CN113903401B (zh) | 基于ctDNA长度的分析方法和系统 | |
CN107523563A (zh) | 一种用于循环肿瘤dna分析的生物信息处理方法 | |
CN105132407B (zh) | 一种脱落细胞dna低频突变富集测序方法 | |
CN105525033A (zh) | 检测血液中微生物的方法及装置 | |
CN114187964A (zh) | 一种肺癌围手术期分子残留病灶基因检测panel及检测模型的构建方法 | |
CN115083521B (zh) | 一种单细胞转录组测序数据中肿瘤细胞类群的鉴定方法及系统 | |
CN114694750A (zh) | 一种基于ngs平台的单样本肿瘤体细胞突变判别及tmb检测方法 | |
WO2021061473A1 (en) | Systems and methods for diagnosing a disease condition using on-target and off-target sequencing data | |
CN116356001B (zh) | 一种基于血液循环肿瘤dna的双重背景噪声突变去除方法 | |
CN113862351B (zh) | 体液样本中鉴定胞外rna生物标志物的试剂盒及方法 | |
CN105779435A (zh) | 试剂盒及其用途 | |
CN117275585A (zh) | 基于lp-wgs和dna甲基化的肺癌早筛模型构建方法及电子设备 | |
CN113362893A (zh) | 肿瘤筛查模型的构建方法及应用 | |
CN112687341B (zh) | 一种以断点为中心的染色体结构变异鉴定方法 | |
CN115331737A (zh) | 一种分析肠道菌群中致病菌和量化菌群地域特征的方法 | |
CN114613436B (zh) | 血样Motif特征提取方法及癌症早筛模型构建方法 | |
RU2766198C9 (ru) | Способы и системы для получения наборов уникальных молекулярных индексов с гетерогенной длиной молекул и коррекции в них ошибок |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Xiao Min Inventor after: Zhu Zhoujie Inventor after: Zhang Wei Inventor after: Yang Xiaoxia Inventor after: Shen Kefeng Inventor after: Zhang Meilan Inventor after: Mu Wei Inventor before: Xiao Min Inventor before: Zhu Zhoujie Inventor before: Zhang Wei Inventor before: Yang Xiaolu Inventor before: Shen Kefeng Inventor before: Zhang Meilan Inventor before: Mu Wei |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |